Click "Show more" for a description of this video, including the Important Safety Information for Berinert®, C1 Esterase Inhibitor (Human). Meet Shari, a Berinert patient. Shari started experiencing HAE symptoms at the age of 11. In this video Shari describes her journey to getting the right diagnosis. B.E.N.® (Berinert Expert Network) P.A.L.S.® (Peer Advocates for Learning and Support) is a unique program that connects new Berinert patients and caregivers with an experienced advocate. B.E.N. P.A.L.S. advocates know what it's like to live with hereditary angioedema (HAE) and have direct experience with Berinert therapy.

Take a moment and listen to these Berinert patients as they share their real-life stories on seeking diagnosis, treatment for HAE, and how the B.E.N. P.A.L.S. Program helped them. Because it's good to know you're not alone.

Your experience with Berinert may not be similar to the individual experiences of the B.E.N. P.A.L.S. participants represented here. B.E.N. P.A.L.S. advocates are not healthcare professionals or medical experts. For medical questions, patients should contact their physicians. B.E.N. P.A.L.S. advocates are compensated by CSL Behring LLC for their time and/or expenses.

The product information in this YouTube video is intended for US residents only.

IMPORTANT SAFETY INFORMATION

Berinert®, C1 Esterase Inhibitor (Human), is for the treatment of ongoing, acute attacks of hereditary angioedema (HAE) affecting the abdomen, face or throat in adults and adolescents. The safety and efficacy of Berinert in preventing HAE attacks have not been established.

Do not use Berinert if you have experienced life-threatening allergic reactions or severe hypersensitivity to the product. Immediately report to your physician or an emergency department any signs or symptoms of allergic reactions to Berinert, including hives, chest tightness, wheezing, turning blue, fast heartbeat, and shock. Also report signs and symptoms of thrombosis that occur after infusing: including swelling and pain in the limbs or abdomen, chest pain, shortness of breath, loss of sensation or motor power, or altered consciousness or speech.

Berinert can be self-administered if you have been trained and advised to do so by your healthcare provider. Seek immediate medical attention if an HAE attack has progressed to a point where you will be unable to prepare or administer Berinert.

Call your doctor right away if swelling is not controlled after use of Berinert.

If you self-administer to treat a laryngeal attack, immediately seek medical attention afterward. If you self-administer for an abdominal attack, inform your physician so that other possible causes can be ruled out.

Because Berinert is made from human blood, the risk that it may transmit infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In clinical studies, the most serious adverse reaction reported in subjects who received Berinert was an increased severity of pain associated with HAE. In the placebo-controlled clinical trial, the most common adverse reaction reported more often among subjects who received Berinert than those receiving placebo was dysgeusia (a bad taste in mouth).

Berinert has not been evaluated in pregnant women or nursing mothers; inform your doctor if you are pregnant or are planning to become pregnant, or if you are breastfeeding or plan to breastfeed. The safety and effectiveness of Berinert have not been established in children under 12 or adults over 65 years of age.

Please see full prescribing information for Berinert, including the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [ Ссылка ], or call 1-800-FDA-1088.

Learn more about Berinert at [ Ссылка ].

B.E.N.® and P.A.L.S.® are registered trademarks of CSL Behring LLC.
Berinert® is a registered trademark of CSL Behring GmbH.

©2013 CSL Behring LLC
1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA
[ Ссылка ] BRN13-05-0066a 7/2013

свернуть